NCT00091182
- Conditions
- Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +99 more
- Locations
-
- Children's Oncology Group Arcadia, California, United States
Clinical trial condition
Recurrent Neuroblastoma
Explore clinical trials studying Recurrent Neuroblastoma. Study availability and eligibility vary by location and protocol.
55 public trials
1 recruiting study
Recurrent Neuroblastoma trial results
Completed
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
NCT00093821
- Conditions
- Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Desmoplastic Small Round Cell Tumor, +36 more
- Locations
-
- Memorial Sloan-Kettering Cancer Center New York, United States
NCT00060372
- Conditions
- Adnexal Diseases, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), +148 more
- Locations
-
- Scripps Clinic - La Jolla La Jolla, California, United States
- University of California San Diego La Jolla, California, United States
- Blood and Marrow Transplant Group of Georgia Atlanta, Georgia, United States
- Northside Hospital Atlanta, Georgia, United States
NCT00005576
- Conditions
- Disseminated Neuroblastoma, Neoplasms, Neoplasms by Histologic Type, +10 more
- Locations
-
- Children's Oncology Group Arcadia, California, United States
NCT03155620
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, +99 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +80 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03213704
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994
- Conditions
- Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States